Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Yasmin Nasser, MD PhD FRCPC
PhD in Neuroscience Department of Physiology and Biophysics University of Calgary, CanadaMD Cumming School of Medicine University of Calgary, Canada
FRCPC Royal College of Physicians and Surgeons of Canada
Areas of Research
Gastrointestinal Sciences - Chronic visceral pain, microbiome
My laboratory is interested in the role of the microbiome in chronic visceral and somatic pain. This pertains to disorders such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Over twenty percent of patients with IBD continue to experience chronic abdominal pain despite achieving mucosal healing on endoscopy. Chronic abdominal pain is a devastating symptom, resulting in high levels of anxiety, depression and poor quality of life in IBD patients. Unfortunately, effective treatments for chronic pain are limited. At present, it is estimated that 5-25% of IBD outpatients are on chronic narcotic therapy, which is not only ineffectual but can worsen abdominal pain and increase the risk of death. Our overall goal is to develop innovative approaches to the treatment of chronic pain in IBD, thus improving quality of life and preventing the use of chronic narcotic therapy.
My laboratory is interested in the role of the microbiome in chronic visceral and somatic pain. This pertains to disorders such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Over twenty percent of patients with IBD continue to experience chronic abdominal pain despite achieving mucosal healing on endoscopy. Chronic abdominal pain is a devastating symptom, resulting in high levels of anxiety, depression and poor quality of life in IBD patients. Unfortunately, effective treatments for chronic pain are limited. At present, it is estimated that 5-25% of IBD outpatients are on chronic narcotic therapy, which is not only ineffectual but can worsen abdominal pain and increase the risk of death. Our overall goal is to develop innovative approaches to the treatment of chronic pain in IBD, thus improving quality of life and preventing the use of chronic narcotic therapy.
Supervising degrees
Gastrointestinal Sciences - Masters: Accepting Inquiries
Working with this supervisor
Please note that I will not be accepting students until January 2018. I am looking for motivated, hard-working individuals who have a passion for research.
Contact this supervisor
Complete the following form if you are interested in working with this supervisor for your Graduate Program. All fields are required, unless indicated otherwise.